<p>2025 年 11 月 28 日- 下午 01:05</p>
<p><strong>收購推進了 INVO 的全國擴張戰略，增強了其臨牀能力，並擴大了中西部地區創新生育護理的可及性</strong></p>
<p>佛羅里達州薩拉索塔和印第安納波利斯，2025 年 11 月 28 日（GLOBE NEWSWIRE）-- INVO Fertility, Inc.（納斯達克：IVF）（“INVO” 或 “公司”）是一家專注於生育診所及相關業務和技術的醫療保健生育公司，今天宣佈其收購 Family Beginnings, P.C.的意圖，該診所是一家受人尊敬的生育診所，為印第安納州及更廣泛的中西部地區的患者提供服務。此次計劃收購標誌着 INVO 在 2023 年收購威斯康星生育研究所後的第二次收購，反映了公司多方位的戰略舉措，旨在建立一個能夠覆蓋服務不足市場並滿足日益增長的患者需求的全國生育中心網絡。</p>
<p>“Family Beginnings 長期以來因其卓越的護理標準而受到認可，我們非常高興能歡迎 James Donahue 博士及其優秀團隊加入 INVO 大家庭，” INVO 首席執行官 Steve Shum 表示。“從我們最初的對話中，很明顯我們在以患者為中心的同情治療理念上有着共同的哲學。同樣令人興奮的是，Donahue 博士是我們創新的 INVOcell 技術的早期採用者，並且仍然是其強有力的倡導者。我們的陰道內培養（“IVC”）解決方案已很好地融入他的實踐中，並且是提供給患者的幾種治療選擇之一。與 Donahue 博士及 Family Beginnings 團隊的合作是我們戰略增長努力的重要一步，我們期待在中西部地區擴大我們的影響力，支持他們的持續成功。”</p>
<p>Family Beginnings 成立於 1990 年代末，已為印第安納州及周邊州的數千名患者提供服務。該診所以個性化護理模式和強大的成功率而聞名，提供全面的生殖服務，包括以下內容：</p>
<ul>
<li>體外受精（IVF）；</li>
<li>INVOcell（IVC）；</li>
<li>子宮內人工授精（IUI）；</li>
<li>第三方生育服務；</li>
<li>生育保存；</li>
<li>高級診斷測試；以及</li>
<li>全面的患者教育和支持項目</li>
</ul>
<p>“我們很高興與 INVO Fertility 攜手合作，” Family Beginnings 的創始人 James Donahue 博士（HCLD）表示。“我們的團隊對幫助個人和家庭實現他們的父母夢想有着深厚的承諾。通過與 INVO 的合作，我們將能夠擴大我們的服務範圍，引入新的創新治療選擇，並確保更多患者受益於我們一直提供的高水平護理。這次合作標誌着我們診所和患者激動人心的新篇章的開始。”</p>
<p>通過此次收購，INVO 計劃增強 Family Beginnings 診所的能力：</p>
<ul>
<li>引入擴展的治療選項；</li>
<li>投資於診所基礎設施和技術，提高工作流程效率；</li>
<li>整合數字患者參與工具，以實現更流暢的溝通和護理協調；以及</li>
<li>利用 INVO 的全國網絡，為患者提供更廣泛的資源、支持項目和臨牀專業知識。</li>
</ul>
<p>“這次收購與我們使命的自然契合，即使生育護理更具可及性和以患者為中心，” Shum 總結道。“像這樣的戰略收購是我們增長計劃的核心組成部分，因為它們使我們能夠加速擴張，同時整合經過驗證的團隊和臨牀基礎設施。我們在一個多月前與 Donahue 博士簽署了條款清單，目前正在完成最終協議，並預計將在近期內完成交易。”</p>
<p>此次收購仍需 INVO 完成常規盡職調查，並與 Family Beginnings 進行談判並簽署最終購買協議。最終協議還預計將包括常規契約、成交條件、任何所需的監管批准、賠償條款和終止權利。不能保證 INVO 將簽署最終協議或完成收購。</p>
<p><strong>關於 INVO Fertility</strong></p>
<p>我們是一家醫療服務生育公司，致力於擴大對需要輔助生殖技術（“ART”）護理的患者的可及性。我們的主要商業戰略集中在建立、收購和運營生育診所，包括主要提供由我們的 INVOcell®醫療設備（“INVOcell”）支持的陰道內培養（“IVC”）程序的 “INVO 中心” 和美國本土的盈利體外受精（“IVF”）診所。我們在美國有兩個運營中的 INVO 中心和一個 IVF 診所。我們還繼續參與向第三方擁有和運營的生育診所銷售和分銷 INVOcell。INVOcell 是一種專有的革命性醫療設備，是首個允許受精和早期胚胎髮育在女性體內進行的設備。IVC 程序為患者提供了比其他 ART 治療更緊密、親密和經濟實惠的體驗。我們相信 IVC 程序可以以傳統 IVF 成本的一小部分提供可比的結果，並且比子宮內人工授精更有效。有關更多信息，請訪問 invofertility.com。</p>
<p><strong>安全港聲明</strong></p>
<p>本公告包含根據《1933 年證券法》第 27A 條及《1934 年證券交易法》第 21E 條的定義的前瞻性聲明。公司引用 1995 年《私人證券訴訟改革法》的保護。所有關於我們預期未來財務狀況、經營成果、現金流、融資計劃、商業戰略、產品和服務、競爭地位、增長機會、管理層未來運營計劃和目標的聲明，以及包含 “預期”、“如果”、“相信”、“計劃”、“估計”、“期望”、“打算”、“可能”、“可以”、“應該”、“將” 等類似表達的聲明均為前瞻性聲明。這些前瞻性聲明包括但不限於關於潛在收購 Family Beginnings 的聲明、任何此類潛在收購的條款和條件、是否會按照非約束性條款清單中規定的條款進行收購（如果有的話），以及收購對 INVO 當前和未來產品供應、業務及財務結果和狀況的影響。所有前瞻性聲明均涉及風險、不確定性和偶發事件，其中許多超出我們的控制，這可能導致實際結果、表現或成就與預期結果、表現或成就有重大差異，包括但不限於 INVO 和 Family Beginnings 無法就 Family Beginnings 業務的非約束性條款清單中規定的條款談判並達成最終購買協議的風險，儘管執行了最終購買協議，INVO 完成此類收購的能力所面臨的監管及其他風險，以及如果收購發生，整合 Family Beginnings 業務的其他風險和不確定性，以及 INVO 是否能從收購中實現其期望的業務、運營和財務結果。導致實際結果與前瞻性聲明中所述結果有重大差異的因素包括我們在 <strong>www.sec.gov</strong> 的文件中列出的因素。我們沒有義務（並明確拒絕任何此類義務）更新或更改我們的前瞻性聲明，無論是由於新信息、未來事件還是其他原因。</p>
<p><strong>如需更多信息，請聯繫：</strong></p>
<p><strong>INVO Fertility, Inc.</strong></p>
<p><strong>Steve Shum, CEO</strong></p>
<p>978-878-9505</p>
<p>sshum@invofertility.com</p>
<p><strong>投資者聯繫</strong></p>
<p><strong>Lytham Partners, LLC</strong></p>
<p><strong>Robert Blum</strong></p>
<p>602-889-9700</p>
<p>INVO@lythampartners.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU16YzVNaU0zTWprMk5EVTBJekl5T1RBNU9Eaz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU16YzVNaU0zTWprMk5EVTBJekl5T1RBNU9Eaz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWIzOGUzOWQtNmVlOC00OTI4LWFlNGMtOTMyNjcyZDlkZDYxLTEzMDI1MzktMjAyNS0xMS0yOC1lbg==/tiny/INVO-Fertility-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWIzOGUzOWQtNmVlOC00OTI4LWFlNGMtOTMyNjcyZDlkZDYxLTEzMDI1MzktMjAyNS0xMS0yOC1lbg==/tiny/INVO-Fertility-Inc-.png"/></p>

<p>INVO Fertility 宣佈其計劃收購位於印第安納州的生育診所 Family Beginnings，作為其全國擴張戰略的一部分。此次收購旨在增強 INVO 的臨牀能力，並擴大中西部地區的生育護理服務。該收購需經過常規盡職調查和最終協議。INVO 計劃在 Family Beginnings 引入更多的治療選擇，並整合數字工具。這一舉措與 INVO 的使命相一致，即使生育護理更加可及和以患者為中心</p>

<p>11/28/2025 - 01:05 PM</p>
<div class="lb-trans"><p>2025 年 11 月 28 日- 下午 01:05</p>
</div><p><strong>Acquisition advances INVO’s national expansion strategy, enhances its clinical capabilities, and broadens access to innovative fertility care across the Midwest</strong></p>
<div class="lb-trans"><p><strong>收購推進了 INVO 的全國擴張戰略，增強了其臨牀能力，並擴大了中西部地區創新生育護理的可及性</strong></p>
</div><p>SARASOTA, Fla. and INDIANAPOLIS, Nov. 28, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced its intent to acquire Family Beginnings, P.C., a respected fertility clinic serving patients across Indiana and the broader Midwest. The planned acquisition marks INVO’s second acquisition after its purchase of Wisconsin Fertility Institute in 2023 and reflects the Company’s multi-pronged strategic initiative to build a nationwide network of fertility centers capable of reaching underserved markets and meeting rising patient demand.</p>
<div class="lb-trans"><p>佛羅里達州薩拉索塔和印第安納波利斯，2025 年 11 月 28 日（GLOBE NEWSWIRE）-- INVO Fertility, Inc.（納斯達克：IVF）（“INVO” 或 “公司”）是一家專注於生育診所及相關業務和技術的醫療保健生育公司，今天宣佈其收購 Family Beginnings, P.C.的意圖，該診所是一家受人尊敬的生育診所，為印第安納州及更廣泛的中西部地區的患者提供服務。此次計劃收購標誌着 INVO 在 2023 年收購威斯康星生育研究所後的第二次收購，反映了公司多方位的戰略舉措，旨在建立一個能夠覆蓋服務不足市場並滿足日益增長的患者需求的全國生育中心網絡。</p>
</div><p>“Family Beginnings has long been recognized for its exceptional standards of care, and we are thrilled to welcome Dr. James Donahue and his talented team into the INVO family,” said Steve Shum, CEO of INVO. “From our earliest conversations, it was clear that we share a common philosophy centered on compassionate, patient-first treatment. Equally as exciting, Dr. Donahue was an early adopter and remains a strong advocate of our innovative INVOcell technology. Our intravaginal culture (“IVC”) solution is well integrated into his practice and is one of the several treatment options offered to patients. Teaming up with Dr. Donahue and the Family Beginnings team is an important step in pursuit of our strategic growth efforts, and we look forward to supporting their continued success as we expand our presence across the Midwest.”</p>
<div class="lb-trans"><p>“Family Beginnings 長期以來因其卓越的護理標準而受到認可，我們非常高興能歡迎 James Donahue 博士及其優秀團隊加入 INVO 大家庭，” INVO 首席執行官 Steve Shum 表示。“從我們最初的對話中，很明顯我們在以患者為中心的同情治療理念上有着共同的哲學。同樣令人興奮的是，Donahue 博士是我們創新的 INVOcell 技術的早期採用者，並且仍然是其強有力的倡導者。我們的陰道內培養（“IVC”）解決方案已很好地融入他的實踐中，並且是提供給患者的幾種治療選擇之一。與 Donahue 博士及 Family Beginnings 團隊的合作是我們戰略增長努力的重要一步，我們期待在中西部地區擴大我們的影響力，支持他們的持續成功。”</p>
</div><p>Founded in the late 1990s, Family Beginnings has served thousands of patients across Indiana and surrounding states. Known for its personalized care model and strong success rates, the clinic offers a full suite of reproductive services, including the following:</p>
<div class="lb-trans"><p>Family Beginnings 成立於 1990 年代末，已為印第安納州及周邊州的數千名患者提供服務。該診所以個性化護理模式和強大的成功率而聞名，提供全面的生殖服務，包括以下內容：</p>
</div><ul>
<li>In vitro fertilization (IVF);</li>
<li>INVOcell (IVC);</li>
<li>Intrauterine insemination (IUI);</li>
<li>Third-party reproduction services;</li>
<li>Fertility preservation;</li>
<li>Advanced diagnostic testing; and</li>
<li>Comprehensive patient education and support programs</li>
</ul>
<div class="lb-trans"><ul>
<li>體外受精（IVF）；</li>
<li>INVOcell（IVC）；</li>
<li>子宮內人工授精（IUI）；</li>
<li>第三方生育服務；</li>
<li>生育保存；</li>
<li>高級診斷測試；以及</li>
<li>全面的患者教育和支持項目</li>
</ul>
</div><p>“We are excited to join forces with INVO Fertility,” said James Donahue M.D., HCLD and founder of Family Beginnings. “Our teams share a deep commitment to helping individuals and families achieve their dreams of parenthood. By partnering with INVO, we will be able to broaden our offerings, introduce new and innovative treatment options, and ensure that even more patients benefit from the high level of care we’ve always provided. This collaboration marks the beginning of an exciting new chapter for our clinic and our patients.”</p>
<div class="lb-trans"><p>“我們很高興與 INVO Fertility 攜手合作，” Family Beginnings 的創始人 James Donahue 博士（HCLD）表示。“我們的團隊對幫助個人和家庭實現他們的父母夢想有着深厚的承諾。通過與 INVO 的合作，我們將能夠擴大我們的服務範圍，引入新的創新治療選擇，並確保更多患者受益於我們一直提供的高水平護理。這次合作標誌着我們診所和患者激動人心的新篇章的開始。”</p>
</div><p>With this acquisition, INVO plans to enhance the Family Beginnings clinic by:</p>
<div class="lb-trans"><p>通過此次收購，INVO 計劃增強 Family Beginnings 診所的能力：</p>
</div><ul>
<li>Introducing expanded treatment options;</li>
<li>Investing in clinic infrastructure and technology, improving workflow efficiencies;</li>
<li>Integrating digital patient engagement tools for streamlined communication and care coordination; and</li>
<li>Leveraging INVO’s national network to provide patients with broader access to resources, support programs, and clinical expertise.</li>
</ul>
<div class="lb-trans"><ul>
<li>引入擴展的治療選項；</li>
<li>投資於診所基礎設施和技術，提高工作流程效率；</li>
<li>整合數字患者參與工具，以實現更流暢的溝通和護理協調；以及</li>
<li>利用 INVO 的全國網絡，為患者提供更廣泛的資源、支持項目和臨牀專業知識。</li>
</ul>
</div><p>“This acquisition is a natural fit with our mission to make fertility care more accessible and patient-centered,” concluded Shum. “Strategic acquisitions like this are a core component of our growth plan, as they allow us to accelerate expansion while integrating proven teams and clinical infrastructure. Having executed a term sheet with Dr. Donahue over a month ago, we are well along in completing final agreements and expect to close the transaction in the near-term.”</p>
<div class="lb-trans"><p>“這次收購與我們使命的自然契合，即使生育護理更具可及性和以患者為中心，” Shum 總結道。“像這樣的戰略收購是我們增長計劃的核心組成部分，因為它們使我們能夠加速擴張，同時整合經過驗證的團隊和臨牀基礎設施。我們在一個多月前與 Donahue 博士簽署了條款清單，目前正在完成最終協議，並預計將在近期內完成交易。”</p>
</div><p>The acquisition remains subject to completion of customary due diligence by INVO and the negotiation and entry into definitive purchase agreements between INVO and Family Beginnings. The definitive agreements are also expected to include customary covenants, closing conditions, any required regulatory approvals, indemnification provisions and termination rights. There can be no assurances that INVO will enter into a definitive agreement or complete the acquisition.</p>
<div class="lb-trans"><p>此次收購仍需 INVO 完成常規盡職調查，並與 Family Beginnings 進行談判並簽署最終購買協議。最終協議還預計將包括常規契約、成交條件、任何所需的監管批准、賠償條款和終止權利。不能保證 INVO 將簽署最終協議或完成收購。</p>
</div><p><strong>About INVO Fertility</strong></p>
<div class="lb-trans"><p><strong>關於 INVO Fertility</strong></p>
</div><p>We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place <em>in vivo</em> within the woman's body. The IVC procedure provides patients with a more connected, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination. For more information, please visit invofertility.com.</p>
<div class="lb-trans"><p>我們是一家醫療服務生育公司，致力於擴大對需要輔助生殖技術（“ART”）護理的患者的可及性。我們的主要商業戰略集中在建立、收購和運營生育診所，包括主要提供由我們的 INVOcell®醫療設備（“INVOcell”）支持的陰道內培養（“IVC”）程序的 “INVO 中心” 和美國本土的盈利體外受精（“IVF”）診所。我們在美國有兩個運營中的 INVO 中心和一個 IVF 診所。我們還繼續參與向第三方擁有和運營的生育診所銷售和分銷 INVOcell。INVOcell 是一種專有的革命性醫療設備，是首個允許受精和早期胚胎髮育在女性體內進行的設備。IVC 程序為患者提供了比其他 ART 治療更緊密、親密和經濟實惠的體驗。我們相信 IVC 程序可以以傳統 IVF 成本的一小部分提供可比的結果，並且比子宮內人工授精更有效。有關更多信息，請訪問 invofertility.com。</p>
</div><p><strong>Safe Harbor Statement</strong></p>
<div class="lb-trans"><p><strong>安全港聲明</strong></p>
</div><p>This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as &#34;anticipate,&#34; &#34;if,&#34; &#34;believe,&#34; &#34;plan,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;could,&#34; &#34;should,&#34; &#34;will,&#34; and other similar expressions are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the potential acquisition of Family Beginnings, the terms and conditions of any such potential acquisition, whether such acquisition will occur on the terms set forth in the non-binding term sheet, if at all, and the impact of the acquisition on INVO’s current and future product offerings, business, and financial results and condition. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements , including but not limited to the risks that INVO and Family Beginnings will not be able to negotiate and enter into a definitive purchase agreement for the Family Beginnings business on terms set forth in the non-binding term sheet or at all, regulatory and other risks associated with INVO’s ability to complete such an acquisition even if a definitive purchase agreement is executed, and, if it occurs, other risks and uncertainties associated with the integration of the Family Beginnings business and whether INVO will achieve its desired or expected business, operational, and financial outcomes from the acquisition. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at <strong>www.sec.gov</strong>. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.</p>
<div class="lb-trans"><p>本公告包含根據《1933 年證券法》第 27A 條及《1934 年證券交易法》第 21E 條的定義的前瞻性聲明。公司引用 1995 年《私人證券訴訟改革法》的保護。所有關於我們預期未來財務狀況、經營成果、現金流、融資計劃、商業戰略、產品和服務、競爭地位、增長機會、管理層未來運營計劃和目標的聲明，以及包含 “預期”、“如果”、“相信”、“計劃”、“估計”、“期望”、“打算”、“可能”、“可以”、“應該”、“將” 等類似表達的聲明均為前瞻性聲明。這些前瞻性聲明包括但不限於關於潛在收購 Family Beginnings 的聲明、任何此類潛在收購的條款和條件、是否會按照非約束性條款清單中規定的條款進行收購（如果有的話），以及收購對 INVO 當前和未來產品供應、業務及財務結果和狀況的影響。所有前瞻性聲明均涉及風險、不確定性和偶發事件，其中許多超出我們的控制，這可能導致實際結果、表現或成就與預期結果、表現或成就有重大差異，包括但不限於 INVO 和 Family Beginnings 無法就 Family Beginnings 業務的非約束性條款清單中規定的條款談判並達成最終購買協議的風險，儘管執行了最終購買協議，INVO 完成此類收購的能力所面臨的監管及其他風險，以及如果收購發生，整合 Family Beginnings 業務的其他風險和不確定性，以及 INVO 是否能從收購中實現其期望的業務、運營和財務結果。導致實際結果與前瞻性聲明中所述結果有重大差異的因素包括我們在 <strong>www.sec.gov</strong> 的文件中列出的因素。我們沒有義務（並明確拒絕任何此類義務）更新或更改我們的前瞻性聲明，無論是由於新信息、未來事件還是其他原因。</p>
</div><p><strong>For more information, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需更多信息，請聯繫：</strong></p>
</div><p><strong>INVO Fertility, Inc.</strong></p>
<div class="lb-trans"><p><strong>INVO Fertility, Inc.</strong></p>
</div><p><strong>Steve Shum, CEO</strong></p>
<div class="lb-trans"><p><strong>Steve Shum, CEO</strong></p>
</div><p>978-878-9505</p>
<div class="lb-trans"><p>978-878-9505</p>
</div><p>sshum@invofertility.com</p>
<div class="lb-trans"><p>sshum@invofertility.com</p>
</div><p><strong>Investor Contact</strong></p>
<div class="lb-trans"><p><strong>投資者聯繫</strong></p>
</div><p><strong>Lytham Partners, LLC</strong></p>
<div class="lb-trans"><p><strong>Lytham Partners, LLC</strong></p>
</div><p><strong>Robert Blum</strong></p>
<div class="lb-trans"><p><strong>Robert Blum</strong></p>
</div><p>602-889-9700</p>
<div class="lb-trans"><p>602-889-9700</p>
</div><p>INVO@lythampartners.com</p>
<div class="lb-trans"><p>INVO@lythampartners.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU16YzVNaU0zTWprMk5EVTBJekl5T1RBNU9Eaz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5Mzc5MiM3Mjk2NDU0IzIyOTA5ODk="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWIzOGUzOWQtNmVlOC00OTI4LWFlNGMtOTMyNjcyZDlkZDYxLTEzMDI1MzktMjAyNS0xMS0yOC1lbg==/tiny/INVO-Fertility-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/YWIzOGUzOWQtNmVlOC00OTI4LWFlNGMtOTMyNjcyZDlkZDYxLTEzMDI1MzktMjAyNS0xMS0yOC1lbg==/tiny/INVO-Fertility-Inc-.png"/></p>

INVO Fertility 宣佈其計劃收購印第安納州的生育診所 “Family Beginnings” | IVF 股票新聞